19171-Myelofibrosis-NA-1384

Myelofibrosis

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/�L) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number:

  • Address

1441 N Beckley Ave, Suite 102
Dallas, TX 75203
P: (214) 943-9911

Search by practice name, trial titles, indicators and specific disease types.